Focus: NeuroGenesis Bio is a public biotechnology company founded in 2007 specializing in bone marrow cell therapy with a focus on oncology and gene therapy applications. The company operates from Rochester, NY and maintains a commercial-stage portfolio with marketed mitomycin-based products.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow NeuroGenesis Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Peak-lifecycle product with 6-year patent protection remaining, indicating current revenue contributor but limited long-term exclusive market potential.
Help build intelligence for NeuroGenesis Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from NeuroGenesis Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Recently launched formulation of mitomycin with identical LOE timeline to JELMYTO, representing portfolio expansion but limited differentiation.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo